SCHEMBL3499489

SCHEMBL3499489

Cc1c(C(=O)NC(C(=O)O)c2c[nH]c3ccccc23)oc2cc(-c3ccc(Cl)cc3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MGAM O43451 3/20 0.39
GAA P10253 3/20 0.39
SI P14410 3/20 0.39
MGAM2 Q2M2H8 3/20 0.39
THRB P10828 1/20 0.39
MMP2 P08253 3/20 0.39
MMP9 P14780 1/20 0.39
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
LMNA P02545 3/20 0.37
MMP13 P45452 2/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13344447 0.92 SMN1; SMN2 (0.40) MCL1SMN1; SMN2MGAMGAASI
SCHEMBL3498156 0.85 MCL1 (0.49) MCL1SMN1; SMN2THRBMMP2KMT2A
SCHEMBL13344446 0.78 TACR3 (0.53) MCL1SMN1; SMN2KMT2AALDH1A1LMNA
SCHEMBL3498868 0.76 KMT2A (0.53) MCL1MMP2KMT2AMEN1
SCHEMBL3498867 0.76 KMT2A (0.53) MCL1MMP2KMT2AMEN1
SCHEMBL3498008 0.76 GPR34 (0.49) KMT2AMEN1
SCHEMBL3499201 0.73 NAALAD2 (0.47) MCL1MMP2KMT2AMEN1
SCHEMBL3500128 0.72 ITGB2 (0.55) SMN1; SMN2MMP2MMP9KMT2AMAPT
SCHEMBL3500127 0.72 ITGB2 (0.55) SMN1; SMN2MMP2MMP9KMT2AMAPT
SCHEMBL3504494 0.72 CAPN1 (0.49) KMT2AALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885SMN1; SMN2 4779/4885MGAM 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.